Key Takeaways
- India Drug Serialization Compliance 2026 requires adherence to both DAVA and Schedule H2 frameworks for regulatory success.
- DAVA mandates unique serialization for all export-bound Schedule H and N drugs with strict data submission requirements.
- Schedule H2 focuses on serialization for the top 300 pharmaceuticals sold domestically, ensuring traceability within the supply chain.
- Manufacturers must achieve full serialization across all packaging levels to avoid compliance risks and potential market complications.
- Integrating both DAVA and Schedule H2 into a unified system is essential for efficient reporting and audit readiness.
Sun Teknovation Pvt Ltd is a Leading Provider of Track & Trace and Machine Vision Solutions for the Global Pharmaceutical Industry.
India is the world's third-largest pharmaceutical producer by volume — and it is now holding its own manufacturers to a standard of traceability that matches many of the regulated export markets they supply. That means the compliance question is no longer just about what the US FDA or EU FMD requires. It is about what India's own regulatory framework demands, right here at home.
Two frameworks define this — DAVA and Schedule H2. Together, they form the Indian Pharma Serialization Framework that governs both what leaves the country and what is sold within it. If your production lines are not configured for both, your compliance picture has gaps — and in a post-2026 enforcement environment, those gaps matter.
Understanding the Two Frameworks
DAVA — For Export-Bound Pharmaceuticals
DAVA Pharma Compliance India sits under the Directorate General of Foreign Trade (DGFT). Launched in 2012, the Drug Authentication and Verification Application (DAVA) mandates serialization for all saleable units of Schedule H and N drugs intended for export — covering high-risk and narcotic drug categories.
Under DAVA Pharma Compliance India, every pack must carry a unique GS1 Data Matrix code at primary, secondary, and tertiary packaging levels. The encoded data must include:
- GTIN (Global Trade Item Number)
- Unique serial number
- Batch number
- Expiry date
- Manufacturing date
Pre-production batch notifications must be submitted to the DAVA portal, and full serialization and aggregation data must be reported at the time of packaging. This is not a declaration process — it is a live data submission requirement tied directly to what happens on your packaging line.
Schedule H2 — For Domestic Drug Serialization
Schedule H2 Serialization Requirements operate under the Central Drugs Standard Control Organisation (CDSCO). This framework targets the Top 300 pharmaceutical brands in India, mandating serialization and traceability for these products in the domestic supply chain.
The technical requirements mirror DAVA closely — GS1 Data Matrix codes across all packaging levels, with the same core data elements encoded and reportable. What differs is the regulatory body, the portal, and the scope of products covered. As the Indian Pharma Serialization Framework matures, the product scope under Schedule H2 is expected to broaden beyond the current Top 300.
Where Manufacturers Are Getting It Wrong
Most manufacturers who believe they are DAVA or Schedule H2 compliant fall into one of three gaps:
Partial serialization coverage — Primary packaging is serialized but secondary and tertiary levels are not aggregated or reported. Both frameworks require serialization across all packaging levels with a verified hierarchy linking units to cases and cases to pallets.
Data submission gaps: Pre-production notifications are overlooked, or serialization data is recorded on the line but never accurately transmitted to the DAVA gateway. Regulators treat this as a reporting failure regardless of whether physical packs carry correct codes.
No validated electronic records — Both frameworks require GMP-compliant, tamper-evident electronic records of every serialization event. Paper-based logging or unvalidated software outputs do not meet this standard under India Drug Serialization Compliance 2026 expectations.
The consequence is not just a compliance finding. For export manufacturers, it can mean export license complications. For domestic manufacturers, it means products in the market that cannot be verified — which is exactly the counterfeiting vulnerability that Drug Traceability India 2026 is designed to eliminate.
What a Compliant System Needs to Deliver
The operational requirements converge on the same technical stack whether you are working for Schedule H2 Serialization Requirements, DAVA Pharma Compliance India, or both:
- Primary, secondary, and tertiary packing GS1 Data Matrix encoding—verified inline at production speed
- Full aggregation — unit to case to pallet, with electronic records at every level
- DAVA portal integration — pre-production notifications and post-packaging serialization data submitted in the required XML format
- Validated electronic records — tamper-evident, audit-trail-complete, GMP-ready documentation
A unified system that covers both DAVA and Schedule H2 within the same platform is the most efficient path — separate setups for each framework create data silos that complicate reporting and audit responses.
How Sun Teknovation Pvt Ltd Supports India Compliance
Sun Teknovation Pvt Ltd.’s online track and trace platform is purpose-built for the Indian Pharma Serialization Framework — covering DAVA and Schedule H2 within a single, validated system. Our solution handles GS1 Data Matrix generation and verification, full multi-level aggregation, and structured data reporting to the DAVA portal in the mandated XML format.
With 14+ years of experience and 1,250+ installations across 60+ countries — including active India-compliance deployments — Sun Teknovation Pvt Ltd brings verified, field-tested knowledge of what India Drug Serialization Compliance 2026 demands at the line level, not just on paper.
Why Choose Us
At Sun Teknovation Pvt Ltd., we do not offer a generic serialization platform adapted for India — we have built a dedicated track and trace solution specifically aligned with DAVA and Schedule H2 Serialization Requirements. Our system covers GS1 Data Matrix coding across all packaging levels, real-time aggregation, DAVA portal data submission, and full GMP-compliant electronic records — everything the Indian Pharma Serialization Framework requires in one integrated platform.Backed by 14+ years of manufacturing expertise and global deployments across DSCSA, EU FMD, BPOM, and DAVA markets, our team understands the practical realities of Drug Traceability India 2026 compliance — and supports your facility through implementation, validation, and ongoing regulatory reporting without leaving gaps.
Conclusion
India's dual serialization framework — DAVA for exports and Schedule H2 for domestic products — represents a maturing regulatory environment that now demands the same technical rigor that global markets have required for years. India Drug Serialization Compliance 2026 is not a distant checkpoint. It is a current enforcement reality for export manufacturers, and an expanding one for domestic producers under Schedule H2 Serialization Requirements.Manufacturers still operating with partial serialization, manual aggregation, or incomplete DAVA portal reporting are carrying compliance risk on every batch they produce. Sun Teknovation Pvt Ltd is ready to help you close those gaps with a validated, India-ready track and trace system built for exactly this framework.Is your serialization setup genuinely ready for DAVA and Schedule H2 audits — or is it covering only part of what India's traceability framework now demands? Connect with Sun Teknovation Pvt Ltd today and get the right system in place before compliance becomes a crisis.
Call us: +91 98982 45695 or Email: connect@sunteknovation.com.
Frequently Asked Questions
Ajay Roshania
Co-Founder & Director (Technical), Sun Teknovation Pvt. Ltd.
Visionary leader driving India’s pharma innovation globally. Expert in turning regulatory challenges into growth opportunities. Leads development of intelligent, future-ready systems that ensure compliance, trust, and scalability. Champion of “Made in India, Trusted Everywhere,” preparing the pharma industry for long-term success.